Drugs and Devices

FDA approves Tanzeum to treat type 2 diabetes

On April 3, the U.S. Food and Drug Administration (FDA) approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Read more.


Related Articles:

One thought on “FDA approves Tanzeum to treat type 2 diabetes”

  1. Yilma says:

    The purpose of the FDA is to protect and promote the health of the public. However, studies show that the FDA approves many products that are causing tremendous harm to the public’s health. In order for the FDA to function properly and safeguard consumers, it needs to be free from unwarranted pharmaceutical industry and corporation influences. Lack of transparency, corruption, and bias prevents the FDA from carrying out its functions.

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares